The study objective is to: 1. To evaluate the effect of sildenafil citrate versus placebo on the IIEF\_EF Domain at the end of the double-blind phase 2. To assess the relationship between treatment with sildenafil citrate or placebo and responses to the Quality of Erection Questionnaire (QEQ) and Sexual Experience Questionnaire (SEX\_Q).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
312
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Moscow, Russia
The primary endpoint is the change from baseline to Visit 4 (Week 8) in the IIEF Erectile Function (EF) domain score.
The change from baseline to visit 6 (wk 12) in the IIEF-EF domain; the change from baseline to visit 4 (wk 8) and visit 6 (wk 12) in the domains and total score as well as the individual questions of the sexual experience questionnaire
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Rostov-on-Don, Russia
Pfizer Investigational Site
Saint Petersburg, Russia
Pfizer Investigational Site
Pusan, South Korea
Pfizer Investigational Site
Seoul, South Korea
Pfizer Investigational Site
Seoul, South Korea
Pfizer Investigational Site
Seoul, South Korea
Pfizer Investigational Site
Seoul, South Korea
...and 9 more locations